Shabnam Hossein

Shabnam Hossein

Auto-generated profile, based on publicly available information

Shabnam Hossein

Department of Psychiatry, University of Pittsburgh, Pittsburgh, USA

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 May 2025 in The British Journal of Psychiatry
Verified
Journal Article
Open access
PDF file
SHShabnam Hossein
Shabnam Hossein
MRManivel Rengasamy
Manivel Rengasamy
AUAiyedun Uzamere
Aiyedun Uzamere
CSCrystal Spotts
Crystal Spotts
RHRobert H. Howland
Robert H. Howland
RPRebecca B. Price
Rebecca B. Price
Background: Understanding the effects of ketamine on depressive symptoms could help identify which patients might benefit and clarify its mechanism of action in both the early (≤1 day post-infusion) and late (e.g. 2–30 days post-infusion) post-infusion periods. Symptom network analyses could provide complementary information regarding relationships between symptoms. Aims: To identify the effects of ketamine on symptom-level changes in depression across both the early and late post-infusion periods and on depressive symptom network changes. Methods: In this secondary analysis of 152 adults with treatment-resistant depression (with 38.8% reporting suicidal ideation at baseline), we compared symptom changes in the early and late post-infusion periods between individuals randomised to a single 40 min infusion of intravenous ketamine 0.5 mg/kg ( n = 103) or saline ( n = 49) and identified changes in symptom networks between pre- and post-ketamine treatment using network analyses. Results: In the early post-infusion period, the greatest improvement (comparing ketamine with saline) was in depressive symptoms related to sadness. In network analyses, symptom network connectivity increased following ketamine infusion. Symptoms of sadness and lassitude showed persistent improvement in the first week post-infusion, whereas improvements in suicidal thoughts first emerged 3–4 weeks post-infusion. Conclusion: Ketamine improved all symptoms but showed the greatest effect on symptoms of sadness, both immediately and in the initial week after treatment. Ketamine also rapidly altered the topology of symptom networks, strengthening interrelationships between residual symptoms. The efficacy of ketamine (compared with saline) regarding suicidal symptoms emerged later. Our findings suggest potentially divergent efficacy, time courses and mechanisms for different symptoms of depression.

27 November 2025 in Translational Psychiatry
Verified
Journal Article
Open access
PDF file
KDKelly R. Donegan
Kelly R. Donegan
SHShabnam Hossein
Shabnam Hossein
BPBenjamin M. Panny
Benjamin M. Panny
VBVanessa M. Brown
Vanessa M. Brown
CLChi Tak Lee
Chi Tak Lee
RPRebecca B Price
Rebecca B Price
Cognitive impairments have been observed in patients with depression. These include deficits in inhibition, shifting, and updating; cognitive processes that are critical for goal-directed control over behavior (‘model-based planning’). Nevertheless, results of model-based planning in depression have been mixed. We aimed to address this by taking a within-person approach, examining model-based planning before and after a range of effective treatments for depression. Across two parallel studies, participants completed a two-step reinforcement learning paradigm before and after antidepressant medication, internet-based cognitive behavioral therapy (iCBT) or intravenous (IV) ketamine infusion. In experiment 1, 93 patients with treatment-resistant depression were randomized to a single dose of IV ketamine (0.5 mg/kg) or IV saline (50 mL 0.9% NaCl). In Experiment 2, 781 participants were followed for four weeks of antidepressant (N = 83), or iCBT (N = 611) treatment. N = 87 participants without any psychiatric diagnosis were followed as a control group. In both experiments, depressive symptoms significantly improved in treatment groups compared to their corresponding control groups, but we did not find evidence of changes in model-based planning. Moreover, we failed to find associations between individual differences in model-based planning and differential response to ketamine, iCBT or antidepressant treatments. Individual differences in model-based planning at baseline were associated with compulsivity, but not with depression symptoms. These findings suggest that model-based planning is not necessarily compromised in depression and does not improve following treatments. This result provides evidence for the trait-like nature of model-based planning and underscores the specificity of its relation to disorders of compulsivity.

25 October 2025 in Journal of Mood & Anxiety Disorders
Verified
Journal Article
Open access
HEH. Nur Eken
H. Nur Eken
SHShabnam Hossein
Shabnam Hossein
AFApphia Freeman
Apphia Freeman
DNDanielle Nebril
Danielle Nebril
KDKevin Do-Nguyen
Kevin Do-Nguyen
RPRebecca B Price
Rebecca B Price
Obsessive-Compulsive Personality Disorder (OCPD) is characterized by a lifelong pattern of excessive attention to detail, rigidity and perfectionism. Although OCPD was historically linked to Obsessive-Compulsive and Related Disorders (OCRDs), this connection lacks consistent evidence. Compulsive behaviors, core to OCRDs, are repetitive actions aimed at reducing distress. To elucidate mechanistic links between OCPD and compulsive behaviors, this study examined relationships between OCPD traits, OCRD symptom domains, and cognitive functioning. In a transdiagnostic sample of 229 adults with reported compulsive behaviors (CBs) enrolled in a larger clinical trial, we assessed maladaptive OCPD traits using the Pathological Obsessive Compulsive Personality Scale (POPS) and examined their associations with a range of OCRD self-report scales, including measures of hair pulling and skin picking. We evaluated cognitive performance using two NIH toolbox tests and a “two-step” reinforcement learning task. OCPD symptom scores correlated positively with OCD symptom severity on the OCI-R (r = 0.42, p < .001) and YBOCS (r = 0.38, p < .001). Higher OCPD scores were also associated with having a larger number of discrete OCRD symptom domains (r = 0.39, p < .001), and with higher scores across the majority of OCRD scales examined. OCPD scores, unlike OCD scores, showed no significant association with Flanker test or two-step task performance. Severity of pathological OCPD traits was related to overall higher severity of OCD symptoms, and linked to several individual domains of OCRDs. Neurocognitive indices showed modest relationships with OCRD symptom severity but not with OCPD. These findings contribute to our understanding of how these phenotypes may co-occur, and help guide future research.